

1 **Metabolomic/lipidomic profiling of COVID-19 and individual**  
2 **response to tocilizumab**

3 Gaia Meoni<sup>a,b,f</sup>, Veronica Ghini<sup>a,c,f</sup>, Laura Maggi<sup>d</sup>, Alessia Vignoli<sup>a,c</sup>, Alessio Mazzoni<sup>d</sup>, Lorenzo  
4 Salvati<sup>d</sup>, Manuela Capone<sup>d</sup>, Anna Vanni<sup>d</sup>, Leonardo Tenori<sup>a,e</sup>, Paolo Fontanari<sup>f</sup>, Federico  
5 Lavorini<sup>d,g</sup>, Adriano Peris<sup>h</sup>, Alessandro Bartoloni<sup>d,i</sup>, Francesco Liotta<sup>d,j</sup>, Lorenzo Cosmi<sup>d,j</sup>, Claudio  
6 Luchinat<sup>a,e</sup>, Francesco Annunziato<sup>d,k\*</sup>, Paola Turano<sup>a,e\*</sup>

7

8 <sup>a</sup>Magnetic Resonance Center (CERM), University of Florence, 50019, Sesto Fiorentino, FI, Italy;

9 <sup>b</sup>Giotto Biotech srl, 50019, Sesto Fiorentino, FI, Italy;

10 <sup>c</sup>Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine (CIRMMP), University of  
11 Florence, 50019, Sesto Fiorentino, FI, Italy;

12 <sup>d</sup>Department of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy;

13 <sup>e</sup>Department of Chemistry "Ugo Schiff", University of Florence, 50019 Sesto Fiorentino, FI, Italy;

14 <sup>f</sup>Cardiac Anaesthesia and Intensive Care Unit, Careggi University Hospital, 50134, FI, Italy;

15 <sup>g</sup>Pneumology and Intensive Care Unit, Careggi University Hospital, 50134, FI, Italy;

16 <sup>h</sup>Intensive Care Unit and Regional ECMO Referral Centre, Careggi University Hospital, 50134, FI,  
17 Italy;

18 <sup>i</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, 50134, FI, Italy; <sup>j</sup>Immunology  
19 and Cell Therapy Unit, Careggi University Hospital, 50134, FI, Italy;

20 <sup>k</sup>Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University Hospital,  
21 50134, FI, Italy

22

23 \*Corresponding authors

24 Paola Turano, Francesco Annunziato;

25 **Email:** [turano@cerm.unifi.it](mailto:turano@cerm.unifi.it) , [francesco.annunziato@unifi.it](mailto:francesco.annunziato@unifi.it).

26 <sup>f</sup>These authors contributed equally;

## 27 **Abstract**

28 The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant  
29 threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical  
30 manifestations, ranging from absence of symptoms to severe forms that need intensive care  
31 treatment. Here, plasma-EDTA samples of 30 patients compared with age- and sex-matched  
32 controls were analyzed via untargeted nuclear magnetic resonance (NMR)-based metabolomics  
33 and lipidomics. With the same approach, the effect of tocilizumab administration was evaluated in  
34 a subset of patients. Despite the heterogeneity of the clinical symptoms, COVID-19 patients are  
35 characterized by common plasma metabolomic and lipidomic signatures (91.7% and 87.5%  
36 accuracy, respectively, when compared to controls). Tocilizumab treatment resulted in at least  
37 partial reversion of the metabolic alterations due to SARS-CoV-2 infection. In conclusion, NMR-  
38 based metabolomic and lipidomic profiling provides novel insights into the pathophysiological  
39 mechanism of human response to SARS-CoV-2 infection and to monitor treatment outcomes.

## 40 **Author summary**

41 The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2  
42 (SARS-CoV-2) is markedly affecting the world population. Here we report about the small-  
43 molecule profile of patients hospitalized during the first wave of the COVID-19 pandemic. Using  
44 magnetic resonance spectroscopy, we showed that the infection induces profound changes in the  
45 metabolome. The analysis of the specific metabolite changes and correlations with clinical data  
46 enabled the identification of potential biochemical determinants of the disease fingerprint. We  
47 also followed how metabolic alterations revert towards those of the control group upon treatment  
48 with tocilizumab, a recombinant humanised monoclonal antibody against the interleukin-6  
49 receptor. These results open up possibilities for the monitoring of novel patients and their  
50 individual response to treatment.

51

## 52 Introduction

53

54 The World Health Organization announced COVID-19 outbreak a pandemic in March 2020 [1,2].

55 At the beginning of October 2020 over thirty-four millions of patients have been diagnosed by

56 SARS-CoV-2 infection and about 1 million deaths are reported all over the world [3]. The SARS-

57 CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence

58 of symptoms to severe forms that need intensive care treatment. About 20% of patients,

59 particularly the older ones and those affected by chronic comorbidities such as hypertension,

60 diabetes mellitus, renal and heart diseases, may develop interstitial pneumonia and respiratory

61 distress requiring oxygen therapy or mechanical ventilation [4]. In addition to interstitial

62 pneumonia and acute respiratory distress syndrome (ARDS), COVID-19 is associated with other

63 life-threatening complications such as sepsis, thromboembolism and multi-organ failure [5].

64 Patients with the highest rate of morbidity and mortality following SARS-CoV-2 infection develop

65 a hyperinflammatory syndrome due to the overproduction of early response proinflammatory

66 cytokines (such as IL-1 $\beta$ , IL-6, TNF $\alpha$ , MCP-1) – the so called “cytokine storm” – leading to an

67 increased vascular permeability, activation of coagulation pathways, dysregulation of T cells with

68 associated lymphopenia, multiorgan injury and rapid clinical deterioration [6–9].

69 Metabolomics and lipidomics can contribute a system level picture, thus expanding the options

70 that chemists can explore to help fight the pandemic [10]. The human metabolome is composed

71 by an ensemble of several thousands of small molecules (<1500–2000 Da) present on a very

72 ample range of concentrations (from <1 nM to >1  $\mu$ M) and produced by the genome of the host

73 organism and by the genomes of its microflora, as well as deriving from exogenous factors like

74 medical treatments [11]. Blood plasma is a primary carrier of small molecules in the body, the

75 relative concentrations of which reflect the physio-pathological state of the organism and thus,

76 possible tissue lesions and organ dysfunctions. The overall picture is complemented by

77 alterations in the lipid components [12]. As a consequence, metabolomics and lipidomics of

78 serum and plasma are increasingly used for successful patient stratification in various diseases

79 [13–18]. Herein, a strong metabolomic and lipidomic signature of COVID-19 is revealed via

80 untargeted nuclear magnetic resonance (NMR) spectroscopy of plasma-EDTA [19,20] from 30  
81 patients compared with age- and sex-matched controls. Moreover, in a subset of patients, the  
82 metabolic effects due to tocilizumab administration were successfully investigated. This study had  
83 no sample-size calculation; the analysis included 30 patients who met the inclusion criteria and  
84 were admitted during the first wave of the pandemic at the local university hospital , before the  
85 rapid decline of hospitalizations for COVID-19.

86

## 87 **Results and Discussion**

88

89 We analyzed via  $^1\text{H}$  NMR spectroscopy the metabolomic and lipidomic profiles of plasma-EDTA  
90 samples obtained from 30 patients affected by coronavirus disease 2019 (COVID-19). SARS-  
91 CoV-2 infection was confirmed by positive RT-PCR on nasopharyngeal swab specimens. The  
92 plasma-EDTA samples available for the metabolomic analysis were collected between 2-23 days  
93 from clinical onset (mean 9 days). Samples from 30 non COVID-19 subjects, one-to-one matched  
94 for age and sex, were used as control group (CTR). Tocilizumab, a humanized anti-IL-6 receptor  
95 monoclonal antibody, was administered to 8 of the 30 COVID-19 patients enrolled and another  
96 plasma-EDTA sample for each patient was collected after 2-18 days of treatment (mean 5 days).  
97 Demographic and clinical characteristics of enrolled patients are reported in S1 Table. Our  
98 analyses considered 21 quantified metabolites and 114 lipoprotein-related parameters [21].  
99 Lipoprotein quantification of plasma samples of two COVID-19 patients (COVID-19-025 and  
100 COVID-19-027) was not possible for the presence of an interfering signal in the spectra, thus also  
101 their respective matched controls (CTR-4 and CTR-7) were removed from the lipoprotein  
102 analyses.

103 No outliers were identified using principal component analysis on the entire population, both for  
104 metabolite and lipoprotein profiles (S1 Fig).

105 Plasma metabolite and lipoprotein profiles of COVID-19 patients and CTRs were compared using  
106 the Random Forest (RF) algorithm. The eight samples collected post-tocilizumab treatment are

107 not included in these analyses. The RF model built on metabolite concentrations shows a  
108 significant differential clustering with 91.7% accuracy, 93.3% sensitivity, and 90.0% specificity  
109 (Figs 1A and C, S2A Fig, Table S2). In particular, a panel of 11 metabolites (Fig 1D, S3 Table)  
110 displays significant alterations between COVID-19 patients and CTRs. One of them, giving rise to  
111 a detectable multiplet signal in the region between 7.21-7.30 ppm has not been assigned and is  
112 referred as “unknown”. However, even if this signal is removed from the statistical model, the  
113 discrimination accuracy between COVID-19 patients and CTRs does not change significantly.

114 The RF model built on lipoprotein-related parameters shows a significant differential clustering  
115 with 87.5% accuracy, 85.7% sensitivity, and 89.3% specificity (Fig 1B-C, S2B Fig, S2 Table).  
116 Forty eight features (Fig 1E, S4 Table) display significant alterations between COVID-19  
117 patients and CTRs. These results demonstrate that COVID-19 patients are characterized by  
118 higher levels of VLDL particles, and lower levels of Apo A1, Apo A2, cholesterol and free-  
119 cholesterol HDL and LDL subfractions. In particular, the subfractions HDL-3, HDL-4, LDL-4, LDL-  
120 5 of cholesterol are the most affected.

121

122 Correlations between clinical and metabolomic parameters were calculated and the results are  
123 reported in Fig 2.

124 Phenylalanine significantly correlates with C-reactive protein (CRP) and interleukin-6.  
125 Inflammation and immune activation impair the conversion of phenylalanine to tyrosine, as  
126 observed in patients suffering from sepsis, cancer, or HIV-1 infection [22–25]; accordingly, we  
127 found higher phenylalanine levels and a trend in lower tyrosine amounts in patients than in  
128 controls. Interestingly, a positive correlation between phenylalanine/tyrosine ratio and high CRP  
129 levels, has been already described by Murr and colleagues [26] in patients affected with coronary  
130 artery disease (CAD). These data are in accordance with ours, since SARS-CoV-2 infection is  
131 characterized not only by immune activation and systemic phlogosis, but also by microvascular  
132 endothelial damage and activation of coagulative cascade, as happens in CAD. Alveolar-arterial  
133 O<sub>2</sub> gradient anticorrelates with citrate, accordingly the partial pressure of arterial oxygen and  
134 fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) ratio (known as Horowitz index) and the ratio between

135 oxygen saturation and fraction of inspired oxygen ( $\text{SaO}_2/\text{FiO}_2$ ) positively correlates with citrate.  
136 This metabolite is known for its anti-oxidative, anti-coagulant and anti-inflammatory properties  
137 [27–29]. SARS-CoV-2 infection can cause lung damage, leading to ARDS, due not only to  
138 alveolar damage but also to diffuse microvascular endothelial damage and clot activation, mainly  
139 driven by pro-inflammatory cytokines, including IL-6 [30,31]. The protective role of citrate on  
140 endothelial integrity was recently reported by Dellepiane and colleagues [32]. Moreover, the  
141 consumption of citrate and other carboxylates is promoted by hypoxic conditions in red blood  
142 cells [33].

143 Formate shows the inverse pattern of correlation with respect to citrate, and it significantly  
144 correlates also with lactate dehydrogenase and  $\text{FiO}_2$ . Regarding lipoprotein-related parameters  
145 only LDL cholesterol significantly correlates with the  $\text{SaO}_2/\text{FiO}_2$  ratio.

146 In line with these observations, metabolites provide an optimal discrimination (accuracy 90.0%,  
147 100.0% sensitivity, 83.3% specificity) between COVID-19 patients treated and non-treated with  
148 invasive ventilation (S3 A-B Fig), with formate and citrate as the most important features of the  
149 model. Instead, no significant clustering is present in the model calculated with lipoprotein-related  
150 parameters (S3 C-D Fig).

151 Despite plasma samples of COVID-19 patients are characterized by higher levels of VLDL and  
152 associated triglycerides, we observed a general reduction of HDL and LDL cholesterol-related  
153 parameters. Downregulation of lipids in COVID-19 blood sera has already been observed [34,35]  
154 and it has been hypothesized that lipids (in particular cholesterol and fatty acids) could play a  
155 pivotal role in virus replication and assembly [36,37]. Our data suggest that only LDL and HDL  
156 could be implied in this mechanism.

157 Accordingly, in a recent study, LDL and HDL levels were inversely correlated to disease severity  
158 and poor prognosis [38]. Furthermore, overproduction of VLDL has been linked with the  
159 processes inducing insulin resistance in COVID-19 patients [35].

160 We also detected an accumulation of mannose in the plasma of COVID-19 patients and a  
161 significant positive correlation between plasma mannose levels and neutrophils and between  
162 mannose and the neutrophils to lymphocytes ratio. An increment of mannose could be related to

163 different reasons: it could be associated to its binding to lectin in order to promote complement  
164 activation [34], or it could be linked to insulin resistance. Indeed, plasma mannose levels are  
165 elevated in subjects with insulin resistance independently of obesity [39] and there are increasing  
166 evidences that a bidirectional relationship between COVID-19 and diabetes exists [40].

167 The increment of pyruvate and 3-hydroxybutyrate, along with the strong decrement of citrate and  
168 free amino acids (alanine, glycine, glutamine, histidine) in plasma of COVID-19 patients can be  
169 ascribed to an impairment of the energetic metabolism. Indeed, during inflammatory states amino  
170 acids can be used to provide energy and materials for the proliferation and phagocytosis of  
171 immune cells. It is important to underline that pyruvate is a metabolite particularly sensitive to pre-  
172 analytical procedures, thus further investigations to confirm its alteration are needed [41,42].

173 Among the 30 COVID-19 patients enrolled, 18 patients presented ARDS. Thus, the possibility  
174 that ARDS could significantly alter the profile of COVID-19 was examined. The RF models  
175 calculated both on metabolites and lipoprotein-related parameters can only slightly cluster ARDS  
176 patients with respect to the other COVID-19 patients (metabolite model: accuracy 76.7%, 88.9%  
177 sensitivity, 58.3% specificity; lipoprotein model: accuracy 75.0%, 81.2% sensitivity, 66.7%  
178 specificity). These results demonstrate that the metabolomic profile of COVID-19 patients is  
179 mainly dictated by the pathology or by the host response to the virus infection, rather than by the  
180 concomitant presence of ARDS.

181

182 Multilevel partial least square discriminant analysis (mPLS-DA) was used to analyze NMR data of  
183 pre- and post-tocilizumab samples in a pairwise multivariate fashion. The mPLS-DA model built  
184 on metabolites shows significant differential clustering, yielding a discrimination accuracy of  
185 80.3% (Fig 3A). The two pairs of samples collected from patients who died (COVID-19-020 and  
186 COVID-19-021) present the smallest shift within the metabolomic subspace. Unfortunately,  
187 COVID-19-018 patient was transferred to another hospital and no follow-up and outcome  
188 information was available. Univariate analysis enables the identification of a panel of eight  
189 metabolites (Fig 3B-I, S5 Table) significantly different (before FDR correction) between pre- and

190 post-tocilizumab patients. The post-treatment levels of these metabolites partially or completely  
191 revert towards the levels of CTR subjects.

192

193 The mPLS-DA model built using lipoprotein-related parameters shows a significant discrimination  
194 between samples collected pre- and post-tocilizumab treatment (accuracy of 82.8%) (S4 Fig).  
195 Univariate analysis identifies 19 lipoprotein parameters (Table S6) significantly different between  
196 pre- and post-tocilizumab treatment. In particular, HDL-1 subfractions of cholesterol,  
197 phospholipids, and Apo A2 showed lower levels at post-treatment, whereas LDL-5, HDL-4, IDL,  
198 VLDL-1, and VLDL-2 of many subfractions are higher at post-treatment. The general increment of  
199 lipoprotein subfractions after treatment confirms the metabolic reversion and supports the key  
200 role of lipids in the metabolism of COVID-19 patients.

201

202 In summary, in this study a strong plasma metabolomic and lipidomic signature of Sars-CoV-2  
203 infection is identified, and it is only marginally affected by the different disease severities.  
204 Additionally, some metabolites correlate with alveolar-capillary membrane injury and their levels  
205 are affected by mechanical ventilation. Of note, in the case of patients who underwent tocilizumab  
206 treatment, metabolic alterations revert towards those of the control group.

207

## 208 **Materials and Methods**

209

### 210 **Study approval**

211 The study was approved by the Comitato Etico Regionale- sezione area vasta centro (protocol  
212 16859) and it complies with the 1964 Declaration of Helsinki and its later amendments. Written  
213 informed consent was obtained from recruited patients.

214

### 215 **Patients characteristics**

216 During the first wave of SARS-CoV-2 infection, 30 patients, hospitalized at the Careggi University  
217 Hospital, Florence, Italy, were enrolled in the study. All patients were of Caucasian ethnicity.  
218 Demographic and clinical features of the enrolled patients are summarized in Table S1.

219

## 220 **Plasma sample preparation**

221 Plasma samples were collected from all the subjects enrolled in the study, according to standard  
222 procedures [41,42]. Blood samples were collected in ethylene diamine tetra-acetate (EDTA)-  
223 coated blood collection tubes and stored at room temperature. Ficoll®, a neutral highly branched  
224 polymer formed by the co-polymerization of sucrose and epichlorohydrin, was used for blood  
225 separation. 14 mL of blood were gently placed in 25 mL tubes containing 9 mL of Ficoll®. Tubes  
226 were centrifugated 1500 g for 20 minutes. Plasma was collected and rapidly stored in a -20°C  
227 freezer pending NMR analysis.

228

## 229 **NMR sample preparation, spectra processing and spectral analysis**

230 NMR samples were prepared according to standard procedures [19,20,43]. NMR spectra for all  
231 samples were acquired using a Bruker 600 MHz spectrometer (Bruker BioSpin) operating at  
232 600.13 MHz proton Larmor frequency and equipped with a 5 mm PATXI  $^1\text{H}$ - $^{13}\text{C}$ - $^{15}\text{N}$  and  $^2\text{H}$ -  
233 decoupling probe including a z-axis gradient coil, an automatic tuning-matching (ATM) and an  
234 automatic refrigerated sample changer (SampleJet, Bruker BioSpin). A BTO 2000 thermocouple  
235 served for temperature stabilization at the level of approximately 0.1 K of the sample. Before  
236 measurement, to equilibrate temperature at 310 K, samples were kept for at least 5 minutes  
237 inside the NMR probe head.

238 For each plasma sample, two one-dimensional  $^1\text{H}$  NMR spectra were acquired with water peak  
239 suppression and different pulse sequences that allowed the selective detection of different  
240 molecular components. The spectra were: 1) a standard NOESY using 32 scans, 98,304 data  
241 points, a spectral width of 18,028 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a  
242 mixing time of 0.01 s. This kind of spectrum is made up of signals arising from low molecular

243 weight molecules (metabolites) and signals arising from macromolecules such as lipoproteins and  
244 lipids; 2) a standard spin echo Carr-Purcell-Meiboom-Gill (CPMG) using 32 scans, 73,728 data  
245 points, a spectral width of 12,019 Hz and a relaxation delay of 4 s. This NMR sequence allows  
246 the selective detection of signals arising only from low molecular weight metabolites.  
247 Before applying Fourier transform, free induction decays were multiplied by an exponential  
248 function equivalent to a 0.3 Hz line-broadening factor. Transformed spectra were automatically  
249 corrected for phase and baseline distortions and calibrated to the anomeric glucose doubled at  $\delta$   
250 5.24 ppm, using TopSpin 3.6.2 (Bruker BioSpin) [19,20].

251

## 252 **Statistical analysis**

253 All data analyses were performed using the “R” statistical environment. Metabolites, whose peaks  
254 in the CPMG spectra were well defined and resolved, were assigned and their concentrations  
255 analyzed. The assignment procedure was performed using an  $^1\text{H}$  NMR spectra library of pure  
256 organic compounds (BBIORFCODE, Bruker BioSpin), public databases, e.g. Human  
257 Metabolome Database [11], storing reference  $^1\text{H}$  NMR spectra of metabolites, and using literature  
258 data when available. The spectral regions associated to the 21 assigned metabolites were  
259 integrated using a R script in-house developed. Quantification of 114 lipid main fractions and  
260 subfractions was performed using the Bruker IVDr platform [21].

261 Both metabolites and lipoprotein-related parameters were analyzed via multivariate analysis.  
262 Unsupervised Principal Component Analysis (PCA) was used as first exploratory analysis to  
263 obtain a preliminary data outlook (*i.e.* cluster detection and screening for outliers). The Random  
264 Forest (RF) algorithm [44] was used for classification in the comparison between COVID-19  
265 patients and CTR. RF is a classification algorithm that uses an ensemble of unpruned decision  
266 trees (forest), each of which is built on a bootstrap sample of the training data using a randomly  
267 selected subset of variables (metabolites or lipoprotein-related parameters)[45,46]. The  
268 percentage of trees in the forest that assign one sample to a specific class can be inferred as a  
269 probability of belonging to a given class [13]. In our case, each tree was used to predict whether a  
270 sample represents a COVID-19 patient or a CTR subject. Because the out-of-bag (OOB)

271 observations were not used in the fitting of the trees, the OOB estimates are cross-validated,  
272 accuracy estimates, and represent an unbiased estimation of the generalization error [44].  
273 Accuracy, sensitivity, and specificity of all calculated models were assessed according to the  
274 standard definitions. For all calculations, the R package ‘Random Forest’ [44] was used to grow a  
275 forest of 1000 trees, using the default settings.

276 Pairwise comparisons between pre- and post-treatment samples were performed using multilevel  
277 Partial Least Square Discriminant Analysis (mPLS-DA) and results validated using a Monte Carlo  
278 Cross-Validation scheme (MCCV, script in house developed): each dataset was randomly divided  
279 by 1000 times into a training set (80% of the data) which was used to build the model and a test  
280 set (20% of the data) which was used to test the integrity of the model. Accuracy, sensitivity, and  
281 specificity of all calculated models were assessed according to the standard definitions.

282 On the biological assumption that metabolite and lipoprotein concentrations are not normally  
283 distributed, non-parametric tests were used for the univariate analysis. Wilcoxon-Mann-Whitney  
284 test was used to infer differences between the metabolite/lipid levels in the comparison between  
285 COVID-19 patients and CTR. Instead for pairwise comparison between pre- and post-treatment  
286 samples the Wilcoxon signed-rank test was utilized [47]. P-values were adjusted for multiple  
287 testing using the false discovery rate (FDR) procedure with Benjamini-Hochberg [48] correction at  
288  $\alpha = 0.05$ . The effect size (Ef) was also calculated [49] to aid in the identification of the meaningful  
289 signals giving an estimation of the magnitude of the separation between the different groups. The  
290 magnitude is assessed using the thresholds provided in Romano et al. [50] , *i.e.*  $|Ef| < 0.147$   
291 “negligible”,  $|Ef| < 0.33$  “small”,  $|Ef| < 0.474$  “medium”, otherwise “large”. Pearson  
292 correlations, adjusted for FDR using BH methods, were also calculated.

293

## 294 **Acknowledgments**

295 P.T., C.L., L.T., V.G., A.V. and G.M. acknowledge the support and the use of resources of  
296 Instruct-ERIC, a Landmark ESFRI project, and specifically the CERM/CIRMMMP Italy Centre. AV  
297 and VG are supported by an AIRC fellowship for Italy. This study was supported by funds from

298 the Department of Experimental and Clinical Medicine of University of Florence, "Excellence  
299 Departments 2018–2022 Project".

300

## 301 **References**

- 302 1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 2 October  
303 2020. [cited 9 Oct 2020]. Available: [https://www.who.int/dg/speeches/detail/who-director-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---2-october-2020)  
304 [general-s-opening-remarks-at-the-media-briefing-on-covid-19---2-october-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---2-october-2020)
- 305 2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak  
306 associated with a new coronavirus of probable bat origin. *Nature*. 2020;579: 270–273.  
307 doi:10.1038/s41586-020-2012-7
- 308 3. Coronavirus Disease (COVID-19) Situation Reports. [cited 9 Oct 2020]. Available:  
309 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- 310 4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus  
311 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases  
312 From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323: 1239–  
313 1242. doi:10.1001/jama.2020.2648
- 314 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality  
315 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*  
316 (London, England). 2020;395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3
- 317 6. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L.  
318 SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine & Growth*  
319 *Factor Reviews*. 2020;54: 62–75. doi:10.1016/j.cytogfr.2020.06.001
- 320 7. Mazzone A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell  
321 cytotoxicity in severe COVID-19 is IL-6 dependent. *The Journal of Clinical Investigation*.  
322 2020;130: 4694–4703. doi:10.1172/JCI113854
- 323 8. Vultaggio A, Vivarelli E, Virgili G, Lucenteforte E, Bartoloni A, Nozzoli C, et al. Prompt  
324 Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients:  
325 Usefulness of a Combined Score Using IL-6 in a Preliminary Study. *J Allergy Clin Immunol*  
326 *Pract*. 2020;8: 2575-2581.e2. doi:10.1016/j.jaip.2020.06.013
- 327 9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected  
328 with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395: 497–506.  
329 doi:10.1016/S0140-6736(20)30183-5
- 330 10. Opatz T, Senn-Bilfinger J, Richert C. Thoughts on What Chemists Can Contribute to  
331 Fighting SARS-CoV-2 – A Short Note on Hand Sanitizers, Drug Candidates and Outreach.  
332 *Angew Chem Int Ed Engl*. 2020;59: 9236–9240. doi:10.1002/anie.202004721
- 333 11. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R, et al. HMDB 4.0:  
334 the human metabolome database for 2018. *Nucleic Acids Research*. 2018;46: D608–D617.  
335 doi:10.1093/nar/gkx1089

- 336 12. Yang K, Han X. Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical  
337 Sciences. *Trends in Biochemical Sciences*. 2016;41: 954–969.  
338 doi:10.1016/j.tibs.2016.08.010
- 339 13. Vignoli A, Tenori L, Giusti B, Takis PG, Valente S, Carrabba N, et al. NMR-based  
340 metabolomics identifies patients at high risk of death within two years after acute  
341 myocardial infarction in the AMI-Florence II cohort. *BMC medicine*. 2019;17: 3.  
342 doi:10.1186/s12916-018-1240-2
- 343 14. Meoni G, Lorini S, Monti M, Madia F, Corti G, Luchinat C, et al. The metabolic fingerprints  
344 of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy.  
345 *Scientific Reports*. 2019;9: 4128. doi:10.1038/s41598-019-40028-4
- 346 15. McCartney A, Vignoli A, Biganzoli L, Love R, Tenori L, Luchinat C, et al. Metabolomics in  
347 breast cancer: A decade in review. *Cancer Treatment Reviews*. 2018;67: 88–96.  
348 doi:10.1016/j.ctrv.2018.04.012
- 349 16. Monnerie S, Comte B, Ziegler D, Morais JA, Pujos-Guillot E, Gaudreau P. Metabolomic and  
350 Lipidomic Signatures of Metabolic Syndrome and its Physiological Components in Adults: A  
351 Systematic Review. *Scientific Reports*. 2020;10: 669. doi:10.1038/s41598-019-56909-7
- 352 17. Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhøffer M, et al.  
353 Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic  
354 Colorectal Cancer. *Cancer Res*. 2012;72: 356–364. doi:10.1158/0008-5472.CAN-11-1543
- 355 18. Zhang L, Zhu B, Zeng Y, Shen H, Zhang J, Wang X. Clinical lipidomics in understanding of  
356 lung cancer: Opportunity and challenge. *Cancer Letters*. 2020;470: 75–83.  
357 doi:10.1016/j.canlet.2019.08.014
- 358 19. Vignoli A, Ghini V, Meoni G, Licari C, Takis PG, Tenori L, et al. High-Throughput  
359 Metabolomics by 1D NMR. *Angew Chem Int Ed Engl*. 2019;58: 968–994.  
360 doi:10.1002/anie.201804736
- 361 20. Takis PG, Ghini V, Tenori L, Turano P, Luchinat C. Uniqueness of the NMR approach to  
362 metabolomics. *TrAC Trends in Analytical Chemistry*. 2019;120: 115300.  
363 doi:10.1016/j.trac.2018.10.036
- 364 21. Jiménez B, Holmes E, Heude C, Tolson RF, Harvey N, Lodge SL, et al. Quantitative  
365 Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and  
366 Plasma by 1H NMR Spectroscopy in a Multilaboratory Trial. *Anal Chem*. 2018;90: 11962–  
367 11971. doi:10.1021/acs.analchem.8b02412
- 368 22. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C,  
369 Ledochowski M, et al. Chronic immune stimulation correlates with reduced phenylalanine  
370 turnover. *Curr Drug Metab*. 2008;9: 622–627. doi:10.2174/138920008785821738
- 371 23. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum  
372 phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations.  
373 *Amino Acids*. 2008;35: 303–307. doi:10.1007/s00726-007-0625-x
- 374 24. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. Increased blood  
375 phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective  
376 antiretroviral therapy. *Brain Behav Immun*. 2010;24: 403–408.  
377 doi:10.1016/j.bbi.2009.11.004

- 378 25. Capuron L, Schroecksnadel S, Féart C, Aubert A, Higuieret D, Barberger-Gateau P, et al.  
379 Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and  
380 tyrosine metabolism: role in neuropsychiatric symptoms. *Biol Psychiatry*. 2011;70: 175–182.  
381 doi:10.1016/j.biopsych.2010.12.006
- 382 26. Murr C, Grammer TB, Meinitzer A, Kleber ME, März W, Fuchs D. Immune activation and  
383 inflammation in patients with cardiovascular disease are associated with higher  
384 phenylalanine to tyrosine ratios: the ludwigshafen risk and cardiovascular health study. *J*  
385 *Amino Acids*. 2014;2014: 783730. doi:10.1155/2014/783730
- 386 27. Grundström G, Christensson A, Alquist M, Nilsson L-G, Segelmark M. Replacement of  
387 acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid  
388 biocompatibility. *BMC Nephrol*. 2013;14: 216. doi:10.1186/1471-2369-14-216
- 389 28. Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M. Citrate- vs. acetate-based dialysate  
390 in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base  
391 status, and electrolytes. *BMC Nephrol*. 2009;10: 7. doi:10.1186/1471-2369-10-7
- 392 29. Marengo M, Dellepiane S, Cantaluppi V. Extracorporeal Treatments in Patients with Acute  
393 Kidney Injury and Sepsis. *Contrib Nephrol*. 2017;190: 1–18. doi:10.1159/000468912
- 394 30. Cipolloni L, Sessa F, Bertozzi G, Baldari B, Cantatore S, Testi R, et al. Preliminary Post-  
395 Mortem COVID-19 Evidence of Endothelial Injury and Factor VIII Hyperexpression.  
396 *Diagnostics (Basel)*. 2020;10. doi:10.3390/diagnostics10080575
- 397 31. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome  
398 coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and  
399 the challenges. *Int J Antimicrob Agents*. 2020;55: 105924.  
400 doi:10.1016/j.ijantimicag.2020.105924
- 401 32. Dellepiane S, Medica D, Guarena C, Musso T, Quercia AD, Leonardi G, et al. Citrate anion  
402 improves chronic dialysis efficacy, reduces systemic inflammation and prevents Chemerin-  
403 mediated microvascular injury. *Scientific Reports*. 2019;9: 10622. doi:10.1038/s41598-019-  
404 47040-8
- 405 33. Nemkov T, Sun K, Reisz JA, Yoshida T, Dunham A, Wen EY, et al. Metabolism of Citrate  
406 and Other Carboxylic Acids in Erythrocytes As a Function of Oxygen Saturation and  
407 Refrigerated Storage. *Front Med*. 2017;4. doi:10.3389/fmed.2017.00175
- 408 34. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic  
409 Characterization of COVID-19 Patient Sera. *Cell*. 2020;182: 59-72.e15.  
410 doi:10.1016/j.cell.2020.05.032
- 411 35. Kimhofer T, Lodge S, Whiley L, Gray N, Loo RL, Lawler NG, et al. Integrative Modeling of  
412 Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan  
413 Pathological Signature of SARS-CoV-2 Infection. *J Proteome Res*. 2020 [cited 12 Oct  
414 2020]. doi:10.1021/acs.jproteome.0c00519
- 415 36. Schoggins JW, Randall G. Lipids in Innate Antiviral Defense. *Cell Host Microbe*. 2013;14:  
416 379–385. doi:10.1016/j.chom.2013.09.010
- 417 37. Abu-Farha M, Thanaraj TA, Qaddoumi MG, Hashem A, Abubaker J, Al-Mulla F. The Role of  
418 Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. *Int J Mol Sci*. 2020;21.  
419 doi:10.3390/ijms21103544

- 420 38. Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. Letter to the Editor: Low-density  
421 lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease  
422 2019. *Metabolism*. 2020;107: 154243. doi:10.1016/j.metabol.2020.154243
- 423 39. Mardinoglu A, Stančáková A, Lotta LA, Kuusisto J, Boren J, Blüher M, et al. Plasma  
424 Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular  
425 Disease. *Cell Metabolism*. 2017;26: 281–283. doi:10.1016/j.cmet.2017.07.006
- 426 40. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-Onset  
427 Diabetes in Covid-19. *New England Journal of Medicine*. 2020;383: 789–790.  
428 doi:10.1056/NEJMc2018688
- 429 41. Bernini P, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P. Standard operating  
430 procedures for pre-analytical handling of blood and urine for metabolomic studies and  
431 biobanks. *J Biomol NMR*. 2011;49: 231–243. doi:10.1007/s10858-011-9489-1
- 432 42. Ghini V, Quaglio D, Luchinat C, Turano P. NMR for sample quality assessment in  
433 metabolomics. *N Biotechnol*. 2019;52: 25–34. doi:10.1016/j.nbt.2019.04.004
- 434 43. PD CEN/TS 16945:2016 - Molecular in vitro diagnostic examinations. Specifications for pre-  
435 examination processes for metabolomics in urine, venous blood serum and plasma. [cited  
436 12 Oct 2020]. Available:  
437 <https://shop.bsigroup.com/ProductDetail?pid=00000000030339067>
- 438 44. Breiman L. Random Forests. *Machine Learning*. 2001;45: 5–32.  
439 doi:10.1023/A:1010933404324
- 440 45. Touw WG, Bayjanov JR, Overmars L, Backus L, Boekhorst J, Wels M, et al. Data mining in  
441 the Life Sciences with Random Forest: a walk in the park or lost in the jungle? *Brief  
442 Bioinform*. 2013;14: 315–326. doi:10.1093/bib/bbs034
- 443 46. Verikas A, Gelzinis A, Bacauskiene M. Mining data with random forests: A survey and  
444 results of new tests. *Pattern Recognition*. 2011;44: 330–349.  
445 doi:10.1016/j.patcog.2010.08.011
- 446 47. Wilcoxon F. Individual Comparisons by Ranking Methods. *Biometrics Bulletin*. 1945;1: 80–  
447 83. doi:10.2307/3001968
- 448 48. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful  
449 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B  
450 (Methodological)*. 1995;57: 289–300.
- 451 49. Rosenthal R. Parametric measures of effect size. *The handbook of research synthesis*.  
452 New York, NY, US: Russell Sage Foundation; 1994. pp. 231–244.
- 453 50. Appropriate statistics for ordinal level data: Should we really be using t-test and Cohen'sd  
454 for evaluating group differences on the NSSE and other surveys? | *BibSonomy*. [cited 12  
455 Oct 2020]. Available:  
456 <https://www.bibsonomy.org/bibtex/216a5c27e770147e5796719fc6b68547d/kweiand>
- 457
- 458

459

460

461

## 462 **Figure legends**

463 **Fig 1. Metabolomic/lipidomic alterations in COVID-19 patients.** (A-B) Proximity plots of the  
464 RF model discriminating COVID-19 patients (red dots), and CTR subjects (green dots) using A)  
465 the 21 quantified metabolites and B) the lipoprotein-related parameters. (C) Confusion matrices  
466 with predictive accuracy values of each model. (D) Values of  $\text{Log}_2$  (Fold Change, (FC) of  
467 quantified metabolites. Grey bars represent p-values  $< 0.05$  after FDR correction. (E) Values of  
468  $\text{Log}_2$ (FC) of lipoprotein-related parameters significantly different (p-value  $< 0.05$  after FDR  
469 correction) between COVID-19 patients and controls. Metabolites/lipoproteins with  $\text{Log}_2$ (FC)  
470 positive/negative values have higher/lower concentration in plasma samples from COVID-19  
471 patients with respect to controls.

472

473 **Fig 2. Heatmap correlations between clinical and metabolomic parameters.** R values are  
474 shown as different degree of color intensity (red, positive correlations; blue, negative correlation).  
475 R values are reported in the plot only for statistically significant correlations (p-value  $< 0.05$  after  
476 FDR correction).

477

478 **Fig 3. Tocilizumab treatment reverts metabolomic/lipidomic alterations in COVID-19**  
479 **patients.** (A) Score plot (of the first two principal components) and accuracy of the mPLS-DA  
480 model discriminating COVID-19 patients at pre- (red dots) and post- (orange dots) tocilizumab  
481 treatment using the 21 quantified metabolites. The code of each patient is reported inside each  
482 dot. Patients 20 and 21 died. (B-I) Boxplots of the statistically significant metabolites  
483 discriminating of pre- (red) and post- (orange) tocilizumab samples, p-values obtained using  
484 Wilcoxon signed-rank test are also reported. Boxplots of controls (green) and the p-values

485 (Wilcoxon-Mann-Whitney test) for the comparison between pre-treatment and CTR are reported.

486 P-values adjusted for FDR are reported in Table S5.

487

## 488 **Supporting information**

489 **S1 Fig. PCA analysis.** Score plots (PC1 vs. PC2) of the unsupervised PCA model of A) 21  
490 quantified metabolites, B) lipoprotein-related parameters; COVID-19 patients (red dots); CTR  
491 subjects (green dots).

492 **S2 Fig. Metabolomic/lipidomic alterations in COVID-19 patients.** Variable importance plots of  
493 the Random Forest models discriminating COVID-19 patients and control subjects. A) 21  
494 quantified metabolites, B) lipoprotein-related parameters.

495 **S3 Fig. Alterations induced by invasive ventilation in COVID-19 patients.** Proximity plot (of  
496 the first two principal components) and accuracy of the Random Forest model discriminating  
497 COVID-19 patients treated (blue dots) and non-treated (sea green dots) with invasive ventilation  
498 using metabolites (A) and lipoprotein-related parameters (C). Variable importance plots of the two  
499 Random Forest models: B) 21 quantified metabolites, D) lipoprotein-related parameters.

500 **S4 Fig. Alterations in lipoprotein profile induced by Tocilizumab treatment.** A) Score plot (of  
501 the first two principal components) and accuracy of the mPLS-DA model discriminating COVID-19  
502 patients pre- (red dots) and post- (orange dots) tocilizumab treatment using the lipoprotein-related  
503 parameters.

504 **S1 Table. Demographic and clinical characteristics of COVID-19 patients.** ACF denotes  
505 acute cardiac failure, AI autoimmune disease, AKI acute kidney injury, ARDS acute respiratory  
506 distress syndrome, CKD chronic kidney disease, CVD cardiovascular disease, D deceased, DBT  
507 type 2 diabetes, DH discharged home, DYS dyslipidemia, H hypertension, K cancer, LTFU lost to  
508 follow-up.

509 **S2 Table. Metabolomic/lipidomic alterations in COVID-19 patients: multivariate analysis.**

510 Random Forest scores of the model discriminating COVID-19 patients and controls using the 21  
511 quantified metabolites and lipoprotein-related parameters. P: predicted class; S: numeric score  
512 (controls:  $0 < S < 0.5$ ; COVID-19 patients:  $0.5 < S < 1$ ).

513 **S3 Table. Metabolomic alterations in COVID-19 patients: univariate analysis.** Univariate

514 analysis of the 21 quantified metabolites for the comparison between COVID-19 patients and  
515 control subjects. The median and MAD of each metabolite in the two groups are reported. The p-  
516 value of the univariate Wilcoxon-Mann-Whitney test together with the p-value calculated after  
517 false discovery rate correction and the effect size, using the Cliff's delta formulation, were also  
518 reported for each metabolite.

519 **S4 Table. Lipidomic alterations in COVID-19 patients: univariate analysis.** Univariate



520 analysis of the lipoprotein-related parameters for the comparison between COVID-19 patients  
521 and control subjects. The median and MAD of each parameter in the two groups are reported.  
522 The p-value of the univariate Wilcoxon-Mann-Whitney test together with the p-value calculated  
523 after false discovery rate correction and the effect size, using the Cliff's delta formulation, were  
524 also reported for each parameter.

525 **S5 Table. Metabolomic alterations induced by Tocilizumab treatment: univariate analysis.**

526 Univariate analysis of the 21 quantified metabolites for the comparison between COVID-19  
527 patients before and after tocilizumab treatment. The p-value of the univariate Wilcoxon-Signed-  
528 Rank test together with the p-value calculated after false discovery rate correction and the effect  
529 size were reported for each metabolite.

530 **S6 Table. Lipidomic alterations induced by Tocilizumab treatment: univariate analysis.**

531 Univariate analysis of the lipoprotein-related parameters for the comparison between COVID-19  
532 patients before and after tocilizumab treatment. The p-value of the univariate Wilcoxon-Signed-  
533 Rank test together with the p-value calculated after false discovery rate correction and the effect  
534 size were reported for each parameter.



**C**

	metabolites		lipoproteins	
	COVID-19	CTR	COVID-19	CTR
COVID-19	28	2	24	4
CTR	3	27	3	25
Predictive accuracy:	91.7%		87.5%	

